Laboratory developed test
Laboratory developed test (LDT) is a term used to refer to a certain class of in vitro diagnostics (IVDs) that, in the U.S., were traditionally regulated under the Clinical Laboratory Improvement Amendments program.[1]
Laboratory-developed tests (LDTs) are a class of in vitro diagnostics (IVDs) designed, manufactured, and used within a single laboratory. They are employed for various medical diagnoses and research applications, offering advantages in flexibility and fostering innovation in the diagnostics field.[2]
United States
In the United States, the Food and Drug Administration (FDA) has determined that while such tests qualify as medical devices, these products could enter the market without prior approval from the agency. In 2014, the FDA announced that it would start regulating some LDTs.[3][4] In general, however, it has not done so, as of April 2019.[5]
As LDTs do not require FDA 510(k) clearance required by other diagnostic tests, they have been viewed as a regulatory loophole by opponents.[6][7]
Direct-to-consumer
Direct-to-consumer tests are regulated as medical devices, although they are not necessarily reviewed by the FDA.[8]
23andMe direct-to-consumer genetic tests were originally offered as LDTs, but the FDA challenged that and forced the company to submit the test for approval as a class II medical device.[9][10]
Companies
Several companies offer lab-developed tests.[3]
Several prominent companies are at the forefront of developing innovative Laboratory Developed Tests solutions, including Adaptive Biotechnologies Corporation, Quest Diagnostics, Roche, and Illumina [2]
Market Overview
The global market for laboratory-developed testing (LDT) is experiencing significant growth, with a projected value of US$ 4582.6 million by 2030 from US$ 3518.7 million in 2023 (CAGR of 3.8%) [2] This growth is driven by advancements in genetic testing, the increasing demand for personalized medicine, and the ongoing expansion of the healthcare and diagnostics sectors [2]
References
- ^ "CLIA Overview". CMS. 11 April 2018.
- ^ a b c d "Laboratory Developed Testing Market to Reach $4582.6 Million". 2024-05-23. Retrieved 2024-05-23.
- ^ a b Pollack, Andrew (2014-07-31). "F.D.A. Acts on Lab Tests Developed In-House". The New York Times. ISSN 0362-4331. Retrieved 2019-05-22.
- ^ "Laboratory Developed Tests". FDA. 26 March 2018.
- ^ "Oversight Of Laboratory-Developed Tests" (PDF). CAP FAQs, Topic: Laboratory-Developed Tests. College of American Pathologists. 2 April 2019. Archived from the original (PDF) on 21 May 2019. Retrieved 15 December 2022.
- ^ Jotwani, Rohan; Boumil, Marcia; Salem, Deeb; Wetterhahn, Madeline; Beninger, Paul (September 2017). "Theranos Experience Exposes Weaknesses in FDA Regulatory Discretion". Clinical Pharmacology in Drug Development. 6 (5): 433–438. doi:10.1002/cpdd.374.
- ^ Duhaime-Ross, Arielle (Nov 17, 2015). "FDA wants to close the loophole that Theranos used, but Republicans don't understand why". The Verge. Retrieved 5 April 2018.
- ^ Health, Center for Devices and Radiological. "In Vitro Diagnostics - Direct-to-Consumer Tests". www.fda.gov. Retrieved 2018-12-02.
- ^ Yarbrough, Knobbe Martens-Daniel K.; Fuller, Michael. "FDA Approval of 23andMe Genomic Test Shows the Way for Direct-to-Consumer Diagnostics | Lexology". Retrieved 2018-12-02.
- ^ "23andMe Warning Letter Climaxes 7-Year Dilemma Over Lab-Developed Tests". MDDI Online. 2014-01-14. Retrieved 2018-12-02.
 | This medical diagnostic article is a stub. You can help Wikipedia by expanding it. |
 | This article related to medical technology is a stub. You can help Wikipedia by expanding it. |
Notes
This article is a direct transclusion of the Wikipedia article and therefore may not meet the same editing standards as LIMSwiki.
